Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Lilly enters $140 million radiopharmaceutical pact
by Rowan Walrath
July 11, 2024
| A version of this story appeared in
Volume 102, Issue 21
Eli Lilly and Company is backing another radiopharmaceutical developer, this time paying San Diego–based Radionetics $140 million up front to make drugs that target a family of proteins called G protein–coupled receptors that are overexpressed on cancer cells. Radionetics will pair small-molecule ligands with radioisotopes purpose fit for their targets. Lilly recently bought another radiopharma firm, Point Biopharma, and partnered with Aktis Oncology.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter